All In Biotech

Drug Trial Radar · NCT04861259

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

83

Actual

Start

Oct 22, 2021

Primary completion

Oct 9, 2025

Study completion Aug 20, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Apr 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.

Conditions

  • Atypical Hemolytic Uremic Syndrome

Interventions

  • CrovalimabDrug

    Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (\>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and every 4 weeks (Q4W) thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight \>= 40kg to \<100kg) or 1020 mg SC (for participants with body weight \>=100kg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Naive Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25Time frame: Baseline up to Week 25 (after 24 weeks on treatment)

Locations

41 sites in 16 countries. Site status is shown where the registry gives one.

  • Univ of CA San Francisco

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Emory Children's Center

    Atlanta, Georgia

  • Washington University

    St Louis, Missouri

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • UT Health Science Center

    San Antonio, Texas

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Santa Casa de Misericordia

    Belo Horizonte, Minas Gerais, Brazil

  • UPECLIN Hospital das Clinicas da Faculdade de Medicina de Botucatu

    Botucatu, São Paulo, Brazil

  • Hospital das Clinicas - FMUSP

    São Paulo, São Paulo, Brazil

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

  • Peking University First Hospital

    Beijing, China

  • Hopital Lapeyronie

    Montpellier, France

  • Hôpital Robert Debré

    Paris, France

  • Hopital Tenon

    Paris, France

  • Klinik II für Nephrologie, Rheumatologie, Diabetologie und Allgemeine Innere Medizin

    Cologne, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Klinik für Nephrologie des Universitätsklinikum Essen

    Essen, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Del- Pesti Centrumkorhaz- Szent Laszlo Korhaz Telephely

    Budapest, Hungary

  • All India Institute Of Medical Sciences (AIIMS)

    New Delhi, National Capital Territory of Delhi, India

  • Rambam Medical Center

    Haifa, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Sheba MC

    Ramat Gan, Israel

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Lazio, Italy

  • A.O. Universitaria S. Martino Di Genova

    Genoa, Liguria, Italy

  • Nagoya University Hospital

    Aichi, Japan

  • Saitama Medical University Hospital

    Saitama, Japan

  • The University of Tokyo Hospital

    Tokyo, Japan

  • Hospital de Especialidades Puerta de Hierro S.A de C.V.

    Zapopan, Mexico

  • Hospital General de México

    Distrito Federal, Mexico CITY (federal District), Mexico

  • Instituto Nacional de Ciencias

    Mexico City, Mexico CITY (federal District), Mexico

  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

    Monterrey, Nuevo León, Mexico

  • Instytut ?Centrum Zdrowia Matki Polki

    Lodz, Poland

  • Complejo Hospitalario Universitario A Coruña (CHUAC)

    A Coruña, Spain

  • Hospital Clinic i Provincial

    Barcelona, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Istanbul University Istanbul Medical Faculty

    Istanbul, Turkey (Türkiye)

  • Kocaeli University Medical Faculty

    Kocaeli, Turkey (Türkiye)

  • Necmettin Erbakan University Meram Medical Faculty

    Konya, Turkey (Türkiye)

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.